Document Detail


Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study.
MedLine Citation:
PMID:  22936007     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer's disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, and 6 weeks, respectively. The primary objective was to evaluate the safety and tolerability of tideglusib with strict criteria for drug escalation or withdrawal. Mini-Mental Status Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog+), word fluency, Geriatric Depression Scale (GDS), and a final Global Clinical Assessment (GCA) were assessed as secondary objectives. Treatment was well tolerated. Adverse events were as frequent in active and placebo groups, except for some moderate, asymptomatic, and fully reversible increases (>2.5 × ULN) of serum transaminases in 6 active cases (p = 0.001). Tideglusib produced positive trends in MMSE, ADAS-cog, GDS, and GCA without statistical significance in this small sample. Responders in MMSE were significantly higher in the active group (p = 0.05). Patients escalated up to 1000 mg/day had a benefit of increases of 1.68 points in the MMSE and 4.72 points in the ADAS-cog+ when compared to placebo. This small pilot study provides valuable safety and efficacy estimates for the treatment of AD patients with tideglusib, currently being confirmed in a larger clinical trial. Due to escalating doses and the small sample size, this trial provides insufficient evidence to support or reject a benefit of tideglusib in AD.
Authors:
Teodoro Del Ser; Klaus C Steinwachs; Hermann J Gertz; María V Andrés; Belén Gómez-Carrillo; Miguel Medina; Joan A Vericat; Pilar Redondo; David Fleet; Teresa León
Related Documents :
9440297 - Affect, cognition, and the emergence of self-knowledge in the toddler offspring of depr...
24372867 - Do we need both cognitive and behavioural components in interventions for depressed moo...
24014137 - The value of impulsivity to define subgroups of addicted individuals differing in perso...
9271977 - Depression after childbirth: the views of medical students and women compared.
14584007 - Depot risperidone for schizophrenia.
9807637 - Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-30
Journal Detail:
Title:  Journal of Alzheimer's disease : JAD     Volume:  -     ISSN:  1875-8908     ISO Abbreviation:  J. Alzheimers Dis.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9814863     Medline TA:  J Alzheimers Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Noscira SA, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intracellular Degradation of Misfolded Tau Protein Induced by Geldanamycin is Associated with Activa...
Next Document:  Longitudinal Stability Evaluation of Biomarkers and Their Correlation in Cerebrospinal Fluid and Pla...